Divi's Laboratories Q4 Results: Cons PAT grows 13% YoY to Rs 751 crore, revenue up 10%; Rs 30 per share dividend announced

Divi's Laboratories released its March quarter results, according to the announcement. Consolidated profit after tax grew 13% year-on-year to Rs 751 crore, while revenue from operations increased 10% to Rs 2,831 crore during the same period. The company's full-year profit after tax for FY26 stood at Rs 2,568 crore, per the release. The board recommended a final dividend of Rs 30 per equity share, indicating confidence in cash generation and shareholder returns.

For Indian pharmaceutical and chemical manufacturers, consistent earnings growth in double digits reflects resilience in both domestic and export markets. Divi's Labs, a prominent player in active pharmaceutical ingredients and contract research services, typically derives strength from stable API demand and expanding specialty chemicals business. The 10% revenue growth paired with 13% profit growth suggests improved operational efficiency and margin expansion—a positive signal for investors monitoring profitability metrics. The dividend announcement demonstrates capital discipline and management confidence in sustaining earnings momentum. Traders should monitor quarterly progression in coming periods, as API sector dynamics, forex headwinds, and raw material costs remain key variables affecting pharmaceutical exporters. The stock's valuation relative to these earnings metrics will be critical for investment decisions in the mid-cap pharma space.

Source: Markets-Economic Times